OOIR: Observatory of International Research

Papers

(The H4-Index of Endocrine Reviews is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Papillary Craniopharyngioma: An Integrative and Comprehensive Review	607
Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway	286
Correction to: “ER Stress in Cardiometabolic Diseases: From Molecular Mechanisms to Therapeutics”	257
Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future	223
DNA Damage and Repair in Thyroid Physiology and Disease	211
Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies	207
Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes	165
Coxsackievirus and Type 1 Diabetes: Diabetogenic Mechanisms and Implications for Prevention	164
LGR4: A New Receptor Member in Endocrine and Metabolic Diseases	124
Molecular Derangements and the Diagnosis of ACTH-Dependent Cushing’s Syndrome	121
A Critical Assessment of Fasting to Promote Metabolic Health and Longevity	114
The Molecular Biology of Midgut Neuroendocrine Neoplasms	110
Effects of Maternal Vitamin D Supplementation on Childhood Health	108
The Pregnancy-Associated Plasma Protein-A (PAPP-A) Story	106
Correction to: “The Congenital and Acquired Mechanisms Implicated in the Etiology of Central Precocious Puberty”	104
Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies	87
Stem Cells and Organs-on-chips: New Promising Technologies for Human Infertility Treatment	86
Recent Advances in the Role of Autophagy in Endocrine-Dependent Tumors	83
The Biology and Clinical Implications of PCSK7	78
The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism	78
Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?	71
Post-translational Modifications: The Signals at the Intersection of Exercise, Glucose Uptake, and Insulin Sensitivity	70
Current Challenges and Future Directions in the Assessment of Glucocorticoid Status	67
Estrogen Receptor Signaling in the Immune System	67
Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas	66

New and Consolidated Therapeutic Options for Pubertal Induction in Hypogonadism: In-depth Review of the Literature	62
Contemporary Biological Insights and Clinical Management of Craniopharyngioma	61
Correction to: “Imaging of Pheochromocytomas and Paragangliomas”	61
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia	60
Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review	58
The Metabolic Role and Therapeutic Potential of the Microbiome	57
Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction	53
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance	53
Imaging of Pheochromocytomas and Paragangliomas	51
Adiponectin and Adiponectin Receptors in Atherosclerosis	51
Subtyping of Primary Aldosteronism by Adrenal Venous Sampling	50
Glycerol and Glycerol-3-Phosphate: Multifaceted Metabolites in Metabolism, Cancer, and Other Diseases	47
International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood	46
Endotrophin, a Key Marker and Driver for Fibroinflammatory Disease	46
Molecular and Clinical Spectrum of Primary Hyperparathyroidism	45
The Cortisol Awakening Response: Regulation and Functional Significance	45
Brown Adipose Tissue—A Translational Perspective	44
Molecular Developments in Parasellar Tumors and Potential Therapeutic Implications	43
Hippo Signaling in the Ovary: Emerging Roles in Development, Fertility, and Disease	43